ECS Botanics Secures a $24 Million Offtake Agreement with MediCann Health for Supply of Medicinal Cannabis

ECS Botanics Secures a $24 Million Offtake Agreement with MediCann Health for Supply of Medicinal Cannabis


ECS Botanics Holdings Ltd (ASX: ECS) (“ECS” or the “Company”) is pleased to advise that it hassecured a binding offtake agreement (“Medicann Offtake Agreement”) to supply medicinal cannabisdried flower over the next five years to MediCann Health. Under the Medicann Offtake Agreement,ECS will supply $24 million of pharmaceutical-grade cannabis dried flower to Perth-based medicinalcannabis company MediCann Health Pty Ltd (“MediCann”) beginning in January 2024. Both ECS andMedicann expect the volumes ordered under the Offtake Agreement to exceed the minimum annualvolumes.

The new Medicann Offtake Agreement follows ECS Botanics securing two binding offtakeagreements in June 2023 (see ASX announcements dated 26 June 2023), underscoring theCompany's strong presence in the B2B sector and highlighting the positive outcomes stemming fromits recent capacity and production enhancements. New protective cropping enclosures andproduction enhancements have been aimed at bolstering crop yields across additional outdoor fieldsand extending growing seasons through improvements to protective cropping enclosures.

MediCann is a leading medicinal cannabis healthcare company that provides patients with access tolocal specialist doctors and pharmacists who have experience prescribing cannabis-basedmedication. Under the offtake agreement, ECS will continue to exclusively supply two strains of GMPmedicinal cannabis dried flower to MediCann.

Commenting on the agreement, ECS Managing Director, Nan-Maree Schoerie said:

"We are excited to announce the expansion of our partnership with MediCann through this newlyextended, long-term supply agreement. MediCann's dedication to putting patients at the forefront of theirbusiness aligns perfectly with our own commitment to delivering top-tier medicinal cannabis. Ourexpertise in cultivating and manufacturing cannabis, combined with our shared focus on patient well-being, inspires us to continue to provide outstanding medicine to companies such as MediCann. Thisagreement not only reinforces our dedication to meeting the growing demand for affordable, accessible, and effective medicinal cannabis products but also marks another milestone following our June 2023agreements, totalling $11.9 million. These partnerships highlight the strong local demand for our GMPcertified, pharmaceutical-grade cannabis and provide ECS with a solid foundation to continue to deliverprofitable growth."

MediCann Founder and CEO, Matt Shales said:

"It has been highly rewarding to work closely with ECS over the past number of years and we aredelighted to strengthen our partnership even further as we secure an exclusive long-term supplyagreement with ECS Botanics for its high-quality Australian grown flowers. We look forward tocontinuing our mission to improve the quality of life of people in need of these products and to continueto build on our partnership with ECS Botanics for the long term."

Key terms of the Medicann Offtake Agreement

The Medicann Offtake Agreement commences on 1 January 2024, until which time Medicann Healthwill continue to be supplied medicinal cannabis dried flower under the current agreement. The OfftakeAgreement stipulates annual volumes of each ECS developed strain that will be supplied exclusivelyby ECS to Medicann Health. Should Medicann not purchase such volumes it will be liable for 80% ofsuch volume not purchased in any calendar year. Termination of, or changes to, the Medicann OfftakeAgreement require mutual agreement.

Authorised on behalf of ECS Botanics Holding Ltd by Nan-Maree Schoerie, Managing Director.

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in NorthwestVictoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in asustainable way, adopting regenerative and organic horticultural practices and renewable energy sources.Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EUagencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordablemedicinal cannabis.

For further information, please contact: info@ecs-botanics.com

Source

The Conversation (0)

Cronos Group Reports 2023 Fourth Quarter and Full-Year Results¹

Ended 2023 with approximately $862 million in cash and short-term investments

Commenced sales to Australian partner

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Trulieve Reports Fourth Quarter and Full Year 2023 Results Highlighting Year End Momentum and Cash Generation

  • Fourth quarter performance delivered highest revenue and gross margin for the year
  • Record cash flow from operations of $202 million and free cash flow of $161 million * in 2023
  • Expect 2024 cash flow from operations of at least $225 million

Trulieve Cannabis Corp . (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced its results for the fourth quarter and full year ended December 31, 2023 . Results are reported in U.S. dollars and in accordance with U.S. Generally Accepted Accounting Principles unless otherwise indicated. Numbers may not sum perfectly due to rounding.

Trulieve logo (PRNewsfoto/Trulieve Cannabis Corp.)

Q4 2023 Financial and Operational Highlights*

  • Revenue of $287 million increased 4% sequentially, with 95% of revenue from retail sales.
  • Achieved GAAP gross margin of 54%, with gross profit of $154 million .
  • Reported net loss of $33 million . Adjusted net loss of $23 million * excludes non-recurring charges, asset impairments, disposals and discontinued operations.
  • Generated cash flow from operations of $131 million and free cash flow of $122 million *.
  • Achieved EBITDA of $73 million *, or 25% of revenue and adjusted EBITDA of $88 million *, or 31% of revenue.
  • Outperformed the third quarter as a result of consumer strength and holiday sales, driven by higher traffic, basket size, and units sold.
  • Redeemed $130 million of senior secured notes due June 18, 2024 on December 1, 2023 .
  • Closed $25 million five-year mortgage financing at 8.31% interest.
  • Filed amended federal tax returns for 2019, 2020, and 2021 claiming $143 million of refunds, also filed corresponding amended state returns claiming $31 million of refunds. Received $62 million in refunds in the fourth quarter and a total of $113 million in refunds to date alongside one rejection notice in the amount of $1.2 million .
  • Relocated one and opened four new dispensaries in Florida .
  • Ended the quarter with 32% of retail locations outside of the state of Florida .

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.
**Fourth quarter results were the highest of the year on an absolute and percentage basis.

2023 Full Year Financial and Operational Highlights*

  • Revenue of $1.13 billion , with 96% of revenue from retail sales.
  • Achieved GAAP gross margin of 52%, with gross profit of $589 million .
  • SG&A expenses lowered by $61 million from prior year to $386 million .
  • Reported net loss of $527 million . Adjusted net loss of $70 million * excludes non-recurring charges, asset and goodwill impairments, disposals and discontinued operations.
  • Generated cash flow from operations of $202 million and free cash flow of $161 million *.
  • Achieved adjusted EBITDA of $322 million *, or 29% of revenue.
  • Purchased $57 million face value senior secured 2026 notes for USD $47.6 million in September, which represents a 16.5% discount to par, plus accrued interest.
  • Cash as of December 31, 2023 of approximately $208 million .
  • Launched adult-use sales in Connecticut and Maryland and opened new markets with medical dispensaries in Georgia and Ohio .
  • Exited California retail assets and operations in Massachusetts as part of cash preservation and generation plan to bolster business resilience.
  • Opened 17 dispensaries in 2023, increasing retail footprint to 192 retail locations nationwide at year end.

*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

Recent Developments

  • The Smart and Safe Florida campaign for adult use presented oral arguments to the Florida Supreme Court in November. The deadline for a ruling is April 1, 2024 .
  • Added two executives to the leadership team in January, Wes Getman , Chief Financial Officer, and Marie Zhang , Chief Operating Officer.
  • Opened one retail location in Pinellas Park, Florida .
  • Currently operate 193 retail dispensaries and over 4 million square feet of cultivation and processing capacity in the United States .

Management Commentary

"Last year we successfully executed on our plan to bolster our business resilience with a focus on cash generation and preservation while making investments to support future growth," said Kim Rivers , Trulieve CEO. "Fourth quarter momentum was underpinned by improved consumer trends. We entered 2024 in a position of significant strength just as the outlook for industry growth and reform brightened. With strong cash generation and a clearly defined strategy, Trulieve is best positioned for the coming wave of meaningful growth catalysts."

Financial Highlights*

Results of Operations

For the Three Months Ended

For the Full Year Ended

(Figures in millions
except per share data and
% change based on these
figures)

December 31,
2023

December 31,
2022

change

September 30,
2023

change

December 31,
2023

December 31,
2022

change

Revenue

$

287

$

298

(4 %)

$

275

4 %

$

1,129

$

1,218

(7 %)

Gross Profit

$

154

$

157

(2 %)

$

143

8 %

$

589

$

689

(15 %)

Gross Margin %


54 %


53 %



52 %



52 %


57 %


Operating Expenses

$

125

$

152

(18 %)

$

120

4 %

$

810

$

639

27 %

Operating Expenses %


43 %


51 %



43 %



72 %


52 %


Net Loss**

$

(33)

$

(77)

(57 %)

$

(25)

32 %

$

(527)

$

(246)

114 %

Net Loss Continuing Ops

$

(37)

$

(64)

(43 %)

$

(23)

60 %

$

(436)

$

(183)

139 %

Adjusted Net Income (Loss)

$

(23)

$

(34)

(33 %)

$

(15)

55 %

$

(70)

$

(19)

272 %

Diluted Shares Outstanding


189


189



189



189


188


EPS Continuing Ops

$

(0.19)

$

(0.33)

(44 %)

$

(0.12)

57 %

$

(2.28)

$

(0.95)

140 %

Adjusted EPS

$

(0.12)

$

(0.18)

(33 %)

$

(0.08)

50 %

$

(0.37)

$

(0.10)

270 %

Adjusted EBITDA

$

88

$

83

6 %

$

78

13 %

$

322

$

398

(19 %)

Adjusted EBITDA Margin %


31 %


28 %



28 %



29 %


33 %


*See "Non-GAAP Financial Measures" below for additional information and a reconciliation to GAAP for all Non-GAAP metrics.

**Net loss includes discontinued operations and non-controlling interest.

Conference Call

The Company will host a conference call and live audio webcast on February 29, 2024, at 8:30 A.M. Eastern time , to discuss its fourth quarter and full year 2023 financial results. Interested parties can join the conference call by dialing in as directed below. Please dial in 15 minutes prior to the call.

North American toll free: 1-844-824-3830


Passcode: 1674609




International: 1-412-542-4136


Passcode: 1674609

A live audio webcast of the conference call will be available at:
https://app.webinar.net/rGl0B9nPzjZ

A powerpoint presentation and archived replay of the webcast will be available at:
https://investors.trulieve.com/events  

The Company's Form 10-K for the year ended December 31, 2023 , will be available on the SEC's website or at https://investors.trulieve.com/quarterly-results . The Company's Management Discussion and Analysis for the period and the accompanying financial statements and notes will be available under the Company's profile on SEDAR and on its website at https://investors.trulieve.com/quarterly-results . This news release is not in any way a substitute for reading those financial statements, including the notes to the financial statements.

Trulieve Cannabis Corp.

Consolidated Balance Sheets (Unaudited)

(in millions, except share data)



December 31,
2023


December 31,
2022

ASSETS




Current Assets:




Cash and cash equivalents

$                 201.4


$              207.2

Restricted cash

6.6


6.6

Accounts receivable, net

6.7


6.5

Inventories

213.1


276.5

Prepaid expenses

17.6


11.0

Other current assets

23.7


51.2

Notes receivable - current portion

6.2


0.7

Assets associated with discontinued operations

2.0


33.7

Total current assets

477.3


593.5

Property and equipment, net

676.4


743.3

Right of use assets - operating, net

95.9


98.9

Right of use assets - finance, net

58.5


70.5

Intangible assets, net

917.2


984.8

Goodwill

483.9


791.5

Notes receivable, net

7.4


12.0

Other assets

10.4


12.8

Long-term assets associated with discontinued operations

2.0


93.1

TOTAL ASSETS

$              2,729.1


$           3,400.4

LIABILITIES




Current Liabilities:




Accounts payable and accrued liabilities

$                   83.2


$                82.0

Income tax payable


49.6

Deferred revenue

1.3


9.5

Notes payable - current portion

3.8


12.5

Operating lease liabilities - current portion

10.1


10.3

Finance lease liabilities - current portion

7.6


8.3

Construction finance liabilities - current portion

1.5


1.2

Contingencies

4.4


34.7

Liabilities associated with discontinued operations

3.0


2.3

Total current liabilities

114.8


210.3

Long-Term Liabilities:




Notes payable, net

115.9


94.2

Private placement notes, net

363.2


541.7

Operating lease liabilities

92.2


99.9

Finance lease liabilities

61.7


69.9

Construction finance liabilities

136.7


137.1

Deferred tax liabilities

207.0


224.9

Uncertain tax position liabilities

180.4


19.5

Other long-term liabilities

7.1


6.8

Long-term liabilities associated with discontinued operations

41.6


68.4

TOTAL LIABILITIES

$              1,320.4


$           1,472.7





SHAREHOLDERS' EQUITY




Common stock, no par value; unlimited shares authorized. 186,235,818 and
185,987,512 shares issued and outstanding as of December 31, 2023 and
December 31, 2022, respectively.

$                       —


$                    —

Additional paid-in-capital

2,055.1


2,045.0

Accumulated deficit

(640.6)


(113.8)

Non-controlling interest

(5.9)


(3.5)

TOTAL SHAREHOLDERS' EQUITY

1,408.6


1,927.7

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$              2,729.1


$           3,400.4

Trulieve Cannabis Corp.

Consolidated Statements of Operations (Unaudited)

(in millions, except for share data)



Three Months Ended


Full Year Ended


December
31, 2023


December
31, 2022


December
31, 2023


December
31, 2022

Revenue

$            287.0


$            298.5


$        1,129.2


$        1,218.2

Cost of goods sold

133.1


141.4


540.6


529.1

Gross profit

153.9


157.1


588.6


689.1

Expenses:








Sales and marketing

59.0


57.9


240.2


277.6

General and administrative

37.3


64.9


146.0


169.5

Depreciation and amortization

27.2


29.8


109.8


116.4

Impairment and disposal of long-lived assets, net

1.2


(0.6)


6.7


75.5

Impairment of goodwill



307.6


Total expenses

124.7


151.9


810.2


639.0

Income (loss) from operations

29.2


5.2


(221.6)


50.2

Other income (expense):








Interest expense, net

(20.6)


(21.2)


(81.6)


(73.4)

Interest income

1.8


0.5


6.2


1.6

Gain on debt extinguishment, net

(2.2)



5.9


Other income (expense), net

0.7


(2.1)


6.5


2.4

Total other (expense) income, net

(20.4)


(22.8)


(62.9)


(69.4)

Income (loss) before provision for income taxes

8.8


(17.6)


(284.5)


(19.2)

Provision for income taxes

45.4


46.6


151.4


163.4

Net loss from continuing operations

(36.6)


(64.2)


(435.9)


(182.6)

Net gain (loss) from discontinued operations, net of tax
benefit (provision) of $21.5, $(2.4), $20.9, and $12.2,
respectively

1.8


(16.9)


(97.2)


(70.1)

Net loss

(34.8)


(81.2)


(533.1)


(252.7)

Less: net loss attributable to non-controlling interest
from continuing operations

(1.4)


(1.4)


(5.1)


(4.0)

Less: net loss attributable to non-controlling interest
from discontinued operations


(2.7)


(1.2)


(2.7)

Net loss attributable to common shareholders

$            (33.4)


$            (77.0)


$          (526.8)


$          (246.1)

Net loss per share - Continuing operations:








Basic and diluted

$            (0.19)


$            (0.33)


$            (2.28)


$            (0.95)

Net loss per share - Discontinued operations:








Basic and diluted

$              0.01


$            (0.08)


$            (0.51)


$            (0.36)

Weighted average number of common shares used in
computing net loss per share:








Basic and diluted

189.0


188.8


189.0


188.0

Trulieve Cannabis Corp.

Consolidated Statements of Cash Flows (Unaudited)

(in millions)



Three Months Ended


Full Year Ended


December
31, 2023


December
31, 2022


December
31, 2023


December
31, 2022

Cash flows from operating activities








Net loss

$            (34.8)


$            (81.2)


$          (533.1)


$          (252.7)

Adjustments to reconcile net loss to net cash provided by
operating activities:








Depreciation and amortization

27.2


30.7


110.8


121.8

Depreciation included in cost of goods sold

14.4


13.4


59.8


52.5

Non-cash interest expense, net

1.2


1.3


5.4


4.9

Gain on extinguishment of debt, net

2.2



(5.9)


Impairment and disposal of long-lived assets, net

1.2


(0.6)


6.7


75.5

Impairment of goodwill



307.6


Amortization of operating lease right of use assets

2.5


2.8


10.3


11.3

Accretion of construction finance liabilities

0.2


0.4


1.3


1.5

Share-based compensation

3.2


3.6


10.6


18.1

Change in fair value of derivative liabilities - warrants



(0.3)


(2.6)

Non-cash change in contingencies

0.8


6.4


(0.5)


23.0

Allowance for credit losses

1.9


1.3


2.8


3.6

Deferred income tax expense

1.5


7.7


(17.2)


(27.2)

Loss from disposal of discontinued operations

(0.4)


0.1


69.5


49.1

Changes in assets and liabilities:








Decrease/(increase) in inventories

16.8


3.7


83.3


(83.4)

Decrease/(increase) in accounts receivable

0.1


0.9


(1.7)


(4.2)

Decrease/(increase) in prepaid expenses and other
current assets

(2.5)


(0.5)


6.8


5.3

Decrease/(increase) in other assets

0.9


6.8


3.0


2.4

(Decrease)/increase in accounts payable and accrued
liabilities

(2.9)


(2.7)


1.6


(0.8)

(Decrease)/increase in income tax payable

1.0


44.4


(48.8)


19.8

(Decrease)/increase in other current liabilities

(0.2)


2.7


(13.3)


(1.4)

(Decrease)/increase in operating lease liabilities

(2.2)


(2.8)


(9.2)


(10.0)

(Decrease)/increase in deferred revenue

(2.2)


3.2


(8.2)


2.4

(Decrease)/increase in uncertain tax position liabilities

99.1


12.5


160.9


12.8

(Decrease)/increase in other long-term liabilities

2.4


1.0


(0.2)


1.5

Net cash provided by operating activities

131.5


55.0


201.8


23.1

Cash flows from investing activities








Purchases of property and equipment

(9.4)


(34.3)


(40.4)


(164.7)

Purchases of property and equipment related to
construction finance liabilities




(13.2)

Capitalized interest


(0.7)


0.1


(4.7)

Acquisitions, net of cash


(1.6)



(27.8)

Divestments


2.0


1.0


2.0

Payments made for issuance of note receivable

(0.8)



(0.8)


Capitalized internal use software

(2.9)


(1.9)


(10.6)


(9.2)

Cash paid for licenses

(0.7)



(4.6)


(1.9)

Proceeds from sales of long-lived assets

0.1


0.2


5.0


0.7

Proceeds received from notes receivable

0.3


0.2


0.9


1.5

Proceeds from sale of held for sale assets

6.0


0.1


11.9


2.3

Net cash used in investing activities

(7.2)


(36.1)


(37.5)


(215.1)

Cash flows from financing activities








Proceeds from notes payable, net of discounts

24.7


89.5


24.7


90.5

Proceeds from private placement notes, net of discounts




75.6

Proceeds from equity exercises




19.4

Proceeds from construction finance liabilities




7.0

Payments on notes payable

(6.3)


(0.2)


(11.8)


(2.9)

Payments on private placement notes

(130.0)



(177.6)


(1.9)

Payments on finance lease obligations

(1.9)


(2.1)


(7.6)


(7.4)

Payments on construction finance liabilities

(0.8)


(0.3)


(2.1)


(1.2)

Payments for debt issuance costs

(0.3)


(0.6)


(0.8)


(0.8)

Payments for taxes related to net share settlement of
equity awards

(0.5)


(0.3)


(0.5)


(0.6)

Distributions



(0.1)


(0.1)

Net cash (used in) provided by financing activities

(115.0)


85.9


(175.6)


177.8

Net increase (decrease) in cash, cash equivalents, and
restricted

9.3


104.8


(11.2)


(14.2)

Cash, cash equivalents, and restricted cash, beginning
of period

198.9


100.7


213.8


229.6

Cash and cash equivalents of discontinued operations,
beginning of period

0.1


14.0


5.7


4.0

Less: cash and cash equivalents of discontinued
operations, end of period

(0.3)


(5.7)


(0.3)


(5.7)

Cash, cash equivalents, and restricted cash, end of
period

$            208.0


$            213.8


$            208.0


$            213.8


The consolidated statements of cash flows include continuing operations and discontinued operations for the periods presented.

Non-GAAP Financial Measures (Unaudited)

In addition to our results determined in accordance with GAAP, we supplement our results with non-GAAP financial measures, including adjusted EBITDA, adjusted net loss (income), adjusted net income (loss) per diluted share and free cash flow. Our management uses these non-GAAP financial measures in conjunction with GAAP financial measures to evaluate our operating results and financial performance. We believe these measures are useful to investors as they are widely used measures of performance and can facilitate comparison to other companies. These non-GAAP financial measures are not, and should not be considered as, measures of liquidity. These non-GAAP financial measures have limitations as analytical tools in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP. Because of these limitations, these non-GAAP financial measures should be considered along with GAAP financial performance measures. The presentation of these non-GAAP financial measures is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures. A reconciliation of the non-GAAP financial measures to such GAAP measures can be found below. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, our reported financial results prepared in accordance with GAAP.

Reconciliation of Non-GAAP Adjusted EBITDA (Unaudited)

The following table presents a reconciliation of GAAP net loss to non-GAAP Adjusted EBITDA, for each of the periods presented:

(Amounts expressed in millions of United States
dollars)

Three Months Ended

For the Full Year Ended

December 31,
2023

December 31,
2022

September 30,
2023

December 31,
2023

December 31,
2022

Net Loss GAAP

$

(33.4)

$

(77.0)

$

(25.4)

$

(526.8)

$

(246.1)

Add (Deduct) Impact of:











Interest Expense, Net

$

20.6

$

21.2

$

20.8

$

81.6

$

73.4

Interest Income (1)

$

(1.8)

$

(0.5)

$

(1.9)

$

(6.2)

$

(1.6)

Provision For Income Taxes

$

45.4

$

46.6

$

36.6

$

151.4

$

163.4

Depreciation and Amortization

$

27.2

$

29.8

$

27.0

$

109.8

$

116.4

Depreciation in COGS

$

14.5

$

12.1

$

14.6

$

57.2

$

46.9

EBITDA

$

72.5

$

32.2

$

71.7

$

(133.0)

$

152.4












Impairment of Goodwill

$

$

$

$

307.6

$

Impairments and Disposals of Long-lived
Assets, Net

$

1.2

$

(0.6)

$

(1.2)

$

6.7

$

75.5

Results of Discontinued Operations

$

(1.8)

$

14.3

$

2.9

$

96.0

$

67.4

Acquisition and Transaction Costs

$

$

7.5

$

$

$

24.8

Integration and Transition Costs

$

10.7

$

4.0

$

8.5

$

26.9

$

21.0

Other Non-Recurring Costs

$

$

7.9

$

$

$

19.5

Share-Based Compensation

$

3.2

$

3.6

$

4.5

$

10.6

$

18.1

Legislative Campaign Contributions

$

0.5

$

10.0

$

0.5

$

20.1

$

20.0

Inventory Step Up Fair Value

$

$

$

$

$

1.0

Covid Related Expenses

$

$

$

$

$

0.8

Loss (Gain) on Debt Extinguishment, Net

$

2.2

$

$

(8.2)

$

(5.9)

$

Other (Income) Expense, Net

$

(0.7)

$

2.1

$

(1.1)

$

(6.5)

$

(2.4)

Results of Entities Not Legally Controlled

$

$

1.9

$

$

$

Adjusted EBITDA Non-GAAP

$

87.8

$

82.9

$

77.6

$

322.3

$

398.2


(1) Interest income for the three months ended December 31, 2022 and September 30, 2023 and the year ended December 31, 2022, of $(0.5) million, $(1.9) million, and $(1.6) million, respectively, was reclassified from other (income) expense, net to interest income in the presentation above.

Reconciliation of Non-GAAP Adjusted Net Income (Loss) (Unaudited)

The following table presents a reconciliation of GAAP net loss to non-GAAP adjusted net loss, for each of the periods presented:


For the Three Months Ended

For the Full Year Ended

(Amounts expressed in millions of United
States dollars)

December 31,
2023

December 31,
2022

September 30,
2023

December 31,
2023

December 31,
2022

Net Loss GAAP

$

(33.4)

$

(77.0)

$

(25.4)

$

(526.8)

$

(246.1)

Add (Deduct) Impact of:











Impairment of Goodwill

$

$

$

$

307.6

$

Fair Value of Derivative Liabilities - Warrants

$

$

(0.0)

$

$

(0.3)

$

(2.6)

Inventory Step Up Fair Value

$

$

$

$

$

1.0

Transaction, Acquisition, and Integration Costs

$

10.7

$

19.4

$

8.5

$

26.9

$

65.3

Legislative Campaign Contributions

$

0.5

$

10.0

$

0.5

$

20.1

$

20.0

Covid Related Expenses

$

$

$

$

$

0.8

Impairments and Disposals of Long-lived
Assets, Net

$

1.2

$

(0.6)

$

(1.2)

$

6.7

$

75.5

Results of Discontinued Operations

$

(1.8)

$

14.3

$

2.9

$

96.0

$

67.4

Adjusted Net (Loss) Income Non-GAAP

$

(22.8)

$

(34.0)

$

(14.7)

$

(69.8)

$

(18.7)

Reconciliation of Non-GAAP Adjusted Earnings (Loss) Per Share (Unaudited)

The following table presents a reconciliation of GAAP loss per share to non-GAAP adjusted earnings per share, for each of the periods presented:


For the Three Months Ended

For the Full Year Ended

(Amounts expressed are per share except for
shares which are in millions)

December 31,
2023

December 31,
2022

September 30,
2023

December 31,
2023

December 31,
2022

Loss Per Share GAAP

$

(0.18)

$

(0.41)

$

(0.13)

$

(2.79)

$

(1.31)

Add (Deduct) Impact of:











Impairment of Goodwill

$

$

$

$

1.63

$

Fair Value of Derivative Liabilities - Warrants

$

$

$

$

(0.00)

$

(0.01)

Inventory Step Up Fair Value

$

$

$

$

$

0.01

Transaction, Acquisition, and Integration Costs

$

0.06

$

0.10

$

0.04

$

0.14

$

0.35

Legislative Campaign Contributions

$

0.00

$

0.05

$

0.00

$

0.11

$

0.11

Covid Related Expenses

$

$

$

$

$

0.00

Impairments and Disposals of Long-lived
Assets, Net

$

0.01

$

(0.00)

$

(0.01)

$

0.04

$

0.40

Results of Discontinued Operations

$

(0.01)

$

0.08

$

0.02

$

0.51

$

0.36

Adjusted Earnings Per Share Non-GAAP

$

(0.12)

$

(0.18)

$

(0.08)

$

(0.37)

$

(0.10)

Basic and Diluted Shares


189.0


188.8


188.9


189.0


188.0

Reconciliation of Non-GAAP Free Cash Flow (Unaudited)

The following table presents a reconciliation of GAAP cash flow from operating activities to non-GAAP free cash flow, for each of the periods presented:


For the Three Months Ended

For the Full Year Ended

(Amounts expressed in millions of United
States dollars)

December 31,
2023

December 31,
2022

September 30,
2023

December 31,
2023

December 31,
2022

Cash Flow From Operating Activities

$

131.5

$

55.0

$

93.4

$

201.8

$

23.1

Payments for Property and Equipment

$

(9.4)

$

(34.3)

$

(6.3)

$

(40.4)

$

(164.7)

Free Cash Flow

$

122.1

$

20.7

$

87.2

$

161.5

$

(141.7)

Forward-Looking Statements

This news release includes forward-looking information and statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to the Company's expectations or forecasts of business, operations, financial performance, prospects, and other plans, intentions, expectations, estimates, and beliefs and include statements regarding the Company's growth opportunities and the Company's positioning for the future. Words such as "expects", "continue", "will", "anticipates" and "intends" or similar expressions are intended to identify forward-looking statements. These forward-looking statements are based on the Company's current projections and expectations about future events and financial trends that management believes might affect its financial condition, results of operations, business strategy and financial needs, and on certain assumptions and analysis made by the Company in light of the experience and perception of historical trends, current conditions and expected future developments and other factors management believes are appropriate. Forward-looking information and statements involve and are subject to assumptions and known and unknown risks, uncertainties, and other factors which may cause actual events, results, performance, or achievements of the Company to be materially different from future events, results, performance, and achievements expressed or implied by forward-looking information and statements herein, including, without limitation, the risks discussed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 and in our periodic reports subsequently filed with the United Sates Securities and Exchange Commission and in the Company's filings on SEDAR at www.sedar.com . Although the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Any forward-looking information and statements herein are made as of the date hereof and, except as required by applicable laws, the Company assumes no obligation and disclaims any intention to update or revise any forward-looking information and statements herein or to update the reasons that actual events or results could or do differ from those projected in any forward looking information and statements herein, whether as a result of new information, future events or results, or otherwise.

About Trulieve

Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with leading market positions in Arizona , Florida , and Pennsylvania . Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com .

Facebook: @Trulieve
Instagram: @Trulieve_
X: @Trulieve

Investor Contact
Christine Hersey , Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com

Media Contact
Phil Buck , APR, Corporate Communications Manager
+1 (406) 370-6226
Philip.Buck@Trulieve.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/trulieve-reports-fourth-quarter-and-full-year-2023-results-highlighting-year-end-momentum-and-cash-generation-302075054.html

SOURCE Trulieve Cannabis Corp.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2024/29/c7462.html

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis leaf with gavel

Germany Becomes Ninth European Nation to Legalize Recreational Cannabis

Germany has approved a bill that would legalize the recreational use and possession of cannabis for adults over the age of 18 as of April 1, 2024, becoming the latest European nation to do so.

The matter was taken to a vote on Friday (February 23) morning in the Bundestag, Germany’s parliament. The debate was reportedly heated, but in the end the measure passed with 407 votes for and 226 against.

Under the new law, German adults will be able to legally possess up to 25 grams of cannabis in public places and 50 grams at home. Smoking cannabis in public will also be allowed, as will home cultivation of up to three plants.

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Pinellas Park, Florida

New Pinellas County location will host grand opening celebration Saturday

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Pinellas Park, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
cannabis leaves, ukraine flag

Cannabis Round-Up: Changes proposed to Canada's excise tax, MSO reports a record-breaking year

After years of lobbying, the Canadian federal government took an important step that may soon result in a reduction to the high excise tax rates paid on cannabis products.

Meanwhile, the University of British Columbia is embarking on a new clinical study that looks into the effects cannabidiol (CBD) may have on the symptoms of bipolar depression, and Verano Holdings (OTCQX:VRNOF) reported good news for shareholders.

Stay up to date on the latest news, trends and policy developments in the cannabis industry with our round-up below.

Keep reading...Show less

Cronos Group Inc. to Hold 2023 Fourth Quarter and Full-Year Earnings Conference Call on February 29, 2024

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) ("Cronos" or the "Company") will hold its 2023 fourth quarter and full-year earnings conference call on Thursday, February 29, 2024 at 8:30 a.m. ET. Cronos' senior management team will discuss the Company's financial results and will be available for questions from the investment community after prepared remarks.

To attend the conference call or webcast, participants should register online at https://ir.thecronosgroup.com/events-presentations . To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast of the call will be archived for replay on the Company's website.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×